In-vivo T-cell depletion with pretransplant anti-thymocyte globulin (ATG) reduces GvHD without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors

被引：0
|
作者：
Kröger, N
Zabelina, T
Krüger, W
Renges, H
Rischewski, J
Ayukatan, F
Tögel, F
Sonnenberg, S
Fiegel, H
Erttmann, R
Schade, U
Zander, A
机构：
来源：
BONE MARROW TRANSPLANTATION | 2002年 / 29卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
O253
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 50 条
  • [21] Impact of rabbit anti-thymocyte globulin (ATG) exposure on outcomes after ex vivo T-cell- depleted hematopoietic cell transplantation in pediatric and young adult patients
    Lakkaraja, Madhavi
    Mauguen, Audrey
    Boulad, Farid
    Cancio, Maria I.
    Curran, Kevin J.
    Harris, Andrew C.
    Kernan, Nancy A.
    Klein, Elizabeth
    Kung, Andrew L.
    Oved, Joseph
    Prockop, Susan
    Scaradavou, Andromachi
    Spitzer, Barbara
    O'Reilly, Richard J.
    Boelens, Jaap Jan
    [J]. CYTOTHERAPY, 2024, 26 (04) : 351 - 359
  • [22] In-vivo T-cell depletion with rabbit anti-thymocyte globulin prevents severe acute- and chronic-graft-versus host disease and allows safe allogeneic stem cell
    Slack, J.
    Leis, J.
    Reeder, C.
    Mikhael, J.
    Noel, P.
    Mesa, R.
    Tibes, R.
    Betcher, J.
    Adams, R.
    [J]. BONE MARROW TRANSPLANTATION, 2012, 47 : S402 - S402
  • [23] Allogeneic stem cell transplantation with matched related and unrelated donors for patients with refractory anemia: T-cell depletion and reduced intensity regimens are associated with increased relapse risk.
    De Witte, TM
    Brand, R
    van Biezen, A
    Guardiola, P
    Barge, R
    Ruutu, T
    Delforge, M
    Arnold, R
    Mufti, G
    Vitek, A
    Finke, J
    Niederwieser, D
    [J]. BLOOD, 2003, 102 (11) : 422A - 422A
  • [24] Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: T-cell depletion and reduced-intensity regimens are associated with an increased relapse risk
    de Witte, T
    Brand, R
    van Biezen, A
    Guardiola, P
    Cornelissen, J
    Gratwohl, A
    Boogaerts, M
    Runde, V
    Arnold, R
    Harrousseau, JL
    Fauser, A
    Mufti, G
    Niederwieser, D
    [J]. BONE MARROW TRANSPLANTATION, 2004, 33 : S255 - S255
  • [25] Donor activating KIR genes significantly influence relapse in leukemia patients after myeloablative conditioning followed by in-vivo T-CELL depleted [ATG] unrelated stem cell transplantation
    Kroeger, Nicolaus
    Binder, Thomas
    Zabelina, Tatjana
    Schieder, Heike
    Renges, Helmut
    Ayuk, Francis
    Wolschke, Christine
    Eiermann, Thomas
    Zander, Axel R.
    [J]. ANNALS OF HEMATOLOGY, 2006, 85 : 26 - 27
  • [26] Effect of myeloablative vs. non-ablative conditioning, graft T-cell depletion and various pretransplant anti-thymocyte globulin (ATG) regimens on the outcome in 144 pediatric patients.
    Seidel, MG
    Lion, T
    Fritsch, G
    Gadner, H
    Peters, C
    [J]. BLOOD, 2003, 102 (11) : 478B - 478B
  • [27] Addition of Anti-thymocyte Globulin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Relapse Free Survival
    Ali, M. M.
    Gronvold, B.
    Remberger, M.
    Abrahamsen, I. W.
    Myhre, A. E.
    Tjonnfjord, G. E.
    Floisand, Y.
    Gedde-Dahl, T.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (09): : 598 - 605
  • [28] In vivo T-cell depletion with pretransplant low-dose antithymocyte globulin is associated with reduced transplant-related mortality and improved clinical outcome in patients receiving allogeneic hematopoietic stem cell transplantation from unrelated and partially matched related donors
    Busca, Alessandro
    Locatelli, Franco
    Flonta, Simona Emilia
    Ciccone, Gianni
    Baldi, Ileana
    D'Ardia, Stefano
    Allione, Bernardino
    Falda, Michele
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (02) : 214 - 217
  • [29] Validation of disease risk index (DRI) in 222 haematological patients receiving allogeneic stem cell transplantation after fludarabine, iv busulfan, and anti-thymocyte globulin (ATG)
    Castagna, L.
    Venton, G.
    Crocchiolo, R.
    El Cheikh, J.
    Fuerst, S.
    Oudin, C.
    Granata, A.
    Vey, N.
    Bouabdallah, R.
    Chabannon, C.
    Blaise, D.
    [J]. BONE MARROW TRANSPLANTATION, 2013, 48 : S254 - S255
  • [30] PROGNOSTIC FACTORS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FROM MATCHED UNRELATED DONORS: LESSONS FROM EXTENDED FOLLOW UP OF A RANDOMIZED TRIAL ON GVHD PROPHYLAXIS WITH OR WITHOUT ANTI T-CELL GLOBULIN ATG-FRESENIUS (ATG-F)
    Finke, J.
    Schmoor, C.
    Bethge, W. A.
    Ottinger, H.
    Stelljes, M.
    Zander, A.
    Volin, L.
    Heim, D.
    Schwerdtfeger, R.
    Bertz, H.
    Grichina, O.
    Socie, G.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S163 - S163
12345